# US 7,745,578 B2 · Fugetactic proteins, compositions and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,745,578 B2
- Document ID: US7745578B2
- Status: Granted
- Kind: B2
- Application number: 10/563,726
- Filed: 2004-07-07
- Published: 2006-12-07
- Granted: 2010-06-29
- Earliest claimed: 2003-07-07
- Assignees: The General Hospital Corporation
- Inventors: Mark C. Poznansky; Dahlia Doughty
- Web page: https://patentgrep.com/patent/US7745578B2

## CPC

- A61K 38/1709: {from mammals}
- A61K 35/26: Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
- A61K 38/17: from animals; from humans {(enzyme inhibitors A61K38/005)}
- A61K 47/646: {the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines}
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/47: from mammals
- G01N 33/5029: {on cell motility}
- G01N 33/505: {involving T-cells}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

This invention relates to compositions and methods that modulate the movement of cells with migratory capacity. More specifically, the invention relates to compositions and methods for promoting migratory movement, fugetaxis, of cells from a specific site in a subject. The foregoing are useful, inter alia, in the treatment of conditions characterized by a need to promote migratory cell movement away from specific sites in a subject. Specific sites include sites of inflammation, infection, an autoimmune reaction, a tumor and a transplanted organ or tissue.

## Claims

### Claim 1

A pharmaceutical composition comprising an isolated heat shock protein (HSP) consisting of SEQ ID NO: 47 in an effective amount to promote fugetactic activity and a pharmaceutically acceptable carrier.

### Claim 2

A method of promoting fugetaxis of migratory cells in a subject, comprising: administering to a subject in need of such treatment the Heat Shock Protein (HSP) of SEQ ID NO:3 or a fragment thereof consisting of SEQ ID NO: 47, in an amount effective to promote fugetaxis of migratory cells away from a stent in a subject.